ArticleExperimental dermatology2026
Plant-Derived Senolytic Ingredient, Camellia sinensis Root Extract, Ameliorates Skin Aging-Associated Phenotypes.
Article in Experimental dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Senescent cells affect neighbouring cells via the senescence-associated secretory phenotype (SASP), which involves proinflammatory cytokines, chemokines and proteases. Camellia sinensis root extract (SENOMUNE) has shown therapeutic potential for skin aging-related disorders. However, whether it exerts senolytic effect remains to be explored. Thus, this study aimed to assess the senolytic properties of SENOMUNE in a stress-induced premature senescence model in normal human dermal fibroblasts (NHDFs) through cell viability assays, quantitative reverse transcription polymerase chain reaction, western blot and flow cytometry. NHDFs were induced to senescence using doxorubicin and insulin-like growth factor-1. The senolytic effect of SENOMUNE was evaluated by measuring senescence-associated β-galactosidase activity, gene and protein expression, and the apoptosis rate. SENOMUNE reduced the viability of senescent cells in a dose-dependent manner, with a more pronounced effect in senescent cells than in control cells. It was also associated with caspase-independent programmed cell death involving apoptosis-inducing factor and lysosomal membrane permeabilization in senescent cells. Moreover, SENOMUNE reduced the production of SASP factors, increased the expression of skin barrier-associated markers, and attenuated pigmentation by modulating the secretion of inflammatory cytokines. These effects were evaluated using conditioned media derived from senescent fibroblasts and validated through ex vivo skin biopsy experiments. Our results suggest that SENOMUNE exhibits senolytic properties and thus is a promising anti-aging phytopharmaceutical ingredient for managing skin-related disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.